OSCIENT PHARMACEUTICALS AND PFIZER ENTER AGREEMENT FOR FACTIVE TABLETS IN MEXICO
Oscient Pharmaceuticals Corporation has sublicensed the commercialization rights
to FACTIVE (gemifloxacin mesylate) tablets in Mexico to Pfizer, S.A. de C.V.,
the largest pharmaceutical company in that country. In exchange for those rights,
Pfizer Mexico has agreed to pay Oscient an up-front payment, milestones for
attaining certain regulatory and sales goals as well as royalties on future
sales. Specific financial terms were not disclosed.